Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Granulysin
Overview
Granulysin is a 15-kDa antimicrobial and cytolytic protein expressed by cytotoxic T lymphocytes and natural killer cells. It disrupts microbial and tumor cell membranes via lipid interactions and induces apoptosis.
Mechanism of Action
The therapeutic rationale includes treatment of intracellular infections and cancer immunotherapy.
Research Summary & Key Findings
Preclinical studies have shown granulysin-mediated killing of mycobacteria, including Mycobacterium tuberculosis, as well as antitumor activity in vitro and in animal models. No clinical trials or approved formulations are currently available, and development remains at the research stage.
Clinical Status
Granulysin is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "Granulysin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Granulysin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Granulysin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Immune
Thymalin
InvestigationalA peptide bioregulator originally extracted from bovine thymus gland, consisting of a mixture of polypeptides that modul...
View detailsLL-37
Research PhaseThe only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide cleaved from the precursor protein h...
View detailsVIP (Vasoactive Intestinal Peptide)
InvestigationalA 28-amino acid neuropeptide widely distributed in the central and peripheral nervous systems and immune cells. VIP acts...
View detailsThymosin Alpha 1 (Zadaxin)
InvestigationalA 28-amino acid peptide originally isolated from thymic tissue (thymosin fraction 5) that serves as a potent immunomodul...
View detailsNo lawful pathway today
Granulysin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.